Trial-Results center  
Clinical trial results database in 100 Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

heart failure - angiotensin-Converting Enzyme Inhibitors - all type of heart failure


Related trials

PEP CHF, 2006 - perindopril vs placebo

ATLAS, 1999 - lisinopril vs lisinopril

Hampton, 1998 - trandolapril vs placebo

NETWORK (2.5 bid vs 10 bid), 1998 - enalapril vs enalapril

NETWORK (5 bid vs 10 bid), 1998 - enalapril vs enalapril

FEST (Erhardt), 1996 - fosinopril vs placebo

Cilazapril-Captopril Multi-centre Group (cila vs capt), 1995 - cilazapril vs captopril

Brown, 1995 - fosinopril vs placebo

CASSIS (spirapril), 1995 - spirapril vs placebo

Cilazapril-Captopril Multi-centre Group (capt vs pbo), 1995 - captopril vs placebo

CASSIS (enalapril), 1995 - enalapril vs placebo

Cilazapril-Captopril Multi-centre Group, 1995 - cilazapril vs placebo

Uprichard-a, 1994 - vs control

Nussberger, 1994 - vs placebo

Gundersen, 1994 - ramipril vs placebo

Uprichard-c, 1994 - vs control

Uprichard-b, 1994 - vs control

Lechat, 1993 - perindopril vs placebo

Gilbert, 1993 - lisinopril vs placebo

Dosseger, 1993 - cilazapril vs placebo

Quinapril Heart Failure Trial Investigators, 1993 - vs placebo

Colfer, 1992 - benazepril vs placebo

SOLVD prevention, 1992 - enalapril vs placebo

Munich MHFT (Kleber), 1992 - captopril vs placebo

Lemarie, 1992 - ramipril vs placebo



See also:

  • All heart failure clinical trials
  • All clinical trials of angiotensin-Converting Enzyme Inhibitors
  • All clinical trials of enalapril
  •  

    V-HeFT II study, 1991

    download pdf: enalapril | angiotensin-Converting Enzyme Inhibitors for heart failure

    Treatments

    Studied treatment enalapril 20mg daily
    Control treatment hydralazine 300 mg plus isosorbide dinitrate 160 mg daily

    Patients

    Patients men with chronic congestive heart failure and cardiac dilatation (CT ratio>0.55) or LVEF <45% in association with reduced exercise tolerance and diuretic therapy
    Exclusion criteria MI or cardiac surgery in prior 3 months; angina limiting exercise; obstructive valvular disease; obstructive pulmonary disease
    Baseline characteristics
    Female (%) 0% 

    Method and design

    Randomized effectives 403 / 401 (studied vs. control)
    Design Parallel groups
    Blinding double blind
    Follow-up duration 2.5y (range 0.5-5.7y)
    Primary endpoint death
    Remarks

    Remarks / Comments



    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    All cause death

    132 / 403
    153 / 401
    0,86 [0,71;1,04]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    All cause death 132 / 403 (32,8%) 153 / 401 (38,2%) 0,86 [0,71;1,04]   0
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

  • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    All cause death 32,75% 38,15% -54,0‰

    Meta-analysis of all similar trials:

    angiotensin-Converting Enzyme Inhibitors in heart failure for all type of heart failure



    Reference(s)

    Trials register # NA
    • Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.. N Engl J Med 1991;325:303-10
      Pubmed | Hubmed | Fulltext

    (c) 2004-2014 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100100